Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 16 (12) , 1954-1963.e3
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health and Welfare, Republic of Korea (HI10C2020)
- Catholic Research Coordinating Center of the Korea Health 21 R&D Project (A070001)
This publication has 15 references indexed in Scilit:
- Hepatocellular carcinoma risk in chronic hepatitis B virus–infected compensated cirrhosis patients with low viral loadHepatology, 2015
- Long‐term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus–related cirrhosisHepatology, 2015
- Meta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosisAlimentary Pharmacology & Therapeutics, 2012
- Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort studyGut, 2011
- Treatment of Hepatitis B in Decompensated Liver CirrhosisInternational Journal of Hepatology, 2011
- Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis BGastroenterology, 2007
- Hepatitis B Virus-Related Cirrhosis: Natural History and TreatmentSeminars in Liver Disease, 2006
- Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2006
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA LevelJAMA, 2006